Search Results - small+molecule

12 Results

Sort By:

Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors

Abstract: Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator...

Published: 4/8/2024 | Inventor(s): Kirk Gustafson, Martin Schnermann, Susanna Chan, Paresma Patel, William Figg, James McMahon

Keywords(s): CANCER, Hypoxia Inhibitor, Malaria, small molecule

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics

Abstract: Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network...

Published: 4/8/2024 | Inventor(s): Joel Schneider, Stephen Miller, Yuji Yamada, Steven Tau, Julie Hixon, Wenqing Li, Caroline Andrews, Scott Walsh

Keywords(s): DEVICE, IL-7, Nanoparticle, Peptide, Peptide-based Hydrogel, Protein, Schneider, small molecule, T Cell Enhancer, Whole Cell Delivery System

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Immunology

Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use

Abstract: Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially...

Published: 4/8/2024 | Inventor(s): Amy Newman, Alessandro Bonifazi, Francisco Battiti, Sophe Cemaj

Keywords(s): D3R agonists, Dopamine, Newman, Parkinson’s Disease, Restless Legs Syndrome, RLS, small molecule

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology

Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents

Abstract: Research and development leading to the discovery of novel antibiotics has waned in recent years. At the same time, the emergence and spread of antimicrobial resistance has compounded the global danger to human health from bacterial infections. The bacterial protein 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a key enzyme...

Published: 4/8/2024 | Inventor(s): Xinhua Ji, Genbin Shi, Gary Shaw

Keywords(s): ANTIBIOTIC, Bacterial Protein, BACTERICIDAL, Biodefense, Broad Spectrum, Folate Biosynthesis, HPPK, Ji, small molecule

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics

Renal Selective Unsaturated Englerin Analogues

Abstract: Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells. Englerin A derivatives are promising treatment strategies for any...

Published: 4/8/2024 | Inventor(s): John Beutler, Tanya Ransom, Antonio Echavarren, Frederic Ratel

Keywords(s): Beutler, DIABETES, HIV, renal cancer, small molecule

Category(s): TherapeuticArea > Endocrinology, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors

Abstract: Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains...

Published: 4/8/2024 | Inventor(s): Giovanna Tosato, Michael Diprima, Harald Schwalbe, Alix Troster, Nathalie Jores, Denis Kudlinzki

Keywords(s): colorectal cancer, Eph Kinase Inhibitors, Eph-related cancers, Ephrin, NVP-BHG712, Regioisomer NVP-Iso, small molecule, solid tumors, Tosato, Tyrosine kinase inhibitors

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Treatment of Prostate Cancer Using Anti-androgen Small Molecules

Abstract: Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target...

Published: 4/8/2024 | Inventor(s): Jane Trepel Neckers, Yeong Kim, Sunmin Lee, Vineet Kumar, Sanjay Malhotra

Keywords(s): Antiandrogen, castrate resistant, CRPC, PROSTATE CANCER, small molecule, steroid hormone receptor.

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...

Published: 7/25/2024 | Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas

Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials

Highly Potent and Selective Deubiquitinating Enzyme Inhibitor

Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...

Published: 7/29/2024 | Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney

Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers

Lactose, found in dairy products and other foods, is comprised of two simple sugars, glucose and galactose. In galactosemia, where galactose is not properly metabolized, build-up of toxic compounds, such as galactose-1-phosphate, can lead to liver disease, renal failure, cataracts, brain damage, and even death if this disorder is left untreated. Currently,...

Published: 7/25/2024 | Inventor(s): Matthew Boxer

Keywords(s): AKT, CANCER, CB7XXX, CBXXXX, CXXXXX, Galactokinase, Galactose, Galactosemia, IBXXXX, Inhibitors, IXXXXX, lactose, Metabolism, PTEN, rare disease, small molecule, UAXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials

1 2